GENFIT Doubles Down on Liver Disease Pipeline as Iqirvo Sales Surge
Event summary
- GENFIT reported €21.1 million in first-half 2026 revenues, driven by €21.0 million in Ipsen royalties.
- Ipsen doubled its peak annual sales target for Iqirvo in PBC to €1 billion, reflecting strong commercial momentum.
- Medicare coverage secured for NASHnext diagnostic test, with U.S. peak sales potential exceeding $1.5 billion by 2033.
- Company to initiate three Phase 2 clinical trials by year-end across ACLF and oncology indications.
- Cash position strengthened to €113.8 million, expected to fund operations beyond 2028.
The big picture
GENFIT's strong first-half 2026 performance underscores the growing commercial potential of its liver disease franchise, particularly through the Ipsen partnership. The company's strategic pivot toward diagnostics and advanced clinical-stage assets positions it to capitalize on both near-term revenue streams and long-term therapeutic breakthroughs. With €113.8 million in cash reserves, GENFIT appears well-positioned to navigate the biotech funding landscape while advancing its high-potential pipeline.
What we're watching
- Commercial Momentum
- Whether Ipsen can sustain Iqirvo's accelerated sales growth across global markets.
- Diagnostic Expansion
- The pace at which NASHnext adoption expands beyond Medicare to private payers.
- Pipeline Execution
- How GENFIT's three Phase 2 trials will impact its ACLF and oncology development strategy.
Related topics